These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 38363461

  • 1. Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis.
    Rams A, Baldasaro J, Bunod L, Delbecque L, Strzok S, Meunier J, ElMaraghy H, Sun L, Pierce E.
    Adv Ther; 2024 Apr; 41(4):1512-1525. PubMed ID: 38363461
    [Abstract] [Full Text] [Related]

  • 2. Sleep-loss related to itch in atopic dermatitis: assessing content validity and psychometric properties of a patient-reported sleep-loss rating scale.
    Rams A, Baldasaro J, Bunod L, Delbecque L, Strzok S, Meunier J, ElMaraghy H, Sun L, Pierce E.
    J Patient Rep Outcomes; 2024 Jul 22; 8(1):77. PubMed ID: 39039395
    [Abstract] [Full Text] [Related]

  • 3. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
    Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbé A, Nelson L, Clark M, Williams N, Chen Z, Ardeleanu M, Akinlade B, Graham NMH, Pirozzi G, Staudinger H, Plaum S, Radin A, Gadkari A.
    Br J Dermatol; 2019 Oct 22; 181(4):761-769. PubMed ID: 30729499
    [Abstract] [Full Text] [Related]

  • 4. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
    Silverberg JI, DeLozier A, Sun L, Thyssen JP, Kim B, Yosipovitch G, Nunes FP, Gugiu PC, Doll HA, Eichenfield LF.
    Health Qual Life Outcomes; 2021 Oct 23; 19(1):247. PubMed ID: 34688290
    [Abstract] [Full Text] [Related]

  • 5. Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS).
    Silverberg JI, Leshem YA, Calimlim BM, McDonald J, Litcher-Kelly L.
    Curr Med Res Opin; 2023 Oct 23; 39(10):1289-1296. PubMed ID: 37691437
    [Abstract] [Full Text] [Related]

  • 6. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS® ) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis.
    Silverberg JI, Lai JS, Patel KR, Singam V, Vakharia PP, Chopra R, Sacotte R, Kantor R, Hsu DY, Cella D.
    Br J Dermatol; 2020 Nov 23; 183(5):891-898. PubMed ID: 32107772
    [Abstract] [Full Text] [Related]

  • 7. Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus.
    Vernon MK, Swett LL, Speck RM, Munera C, Spencer RH, Wen W, Menzaghi F.
    J Patient Rep Outcomes; 2021 Dec 24; 5(1):134. PubMed ID: 34952964
    [Abstract] [Full Text] [Related]

  • 8. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
    Kimel M, Zeidler C, Kwon P, Revicki D, Ständer S.
    JAMA Dermatol; 2020 Dec 01; 156(12):1354-1358. PubMed ID: 32936233
    [Abstract] [Full Text] [Related]

  • 9. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
    Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, Hijnen D, Calimlim BM, Lee WJ, Teixeira HD, Hu X, Zhang S, Yang Y, Grada A, Platt AM, Thaçi D.
    Am J Clin Dermatol; 2024 May 01; 25(3):485-496. PubMed ID: 38528257
    [Abstract] [Full Text] [Related]

  • 10. Worst Itch Numeric Rating Scale for Prurigo Nodularis: A Secondary Analysis of 2 Randomized Clinical Trials.
    Kwatra SG, Yosipovitch G, Kim B, Stander S, Rhoten S, Ivanescu C, Haeusler N, Brookes E, Msihid J, Makhija M, Bansal A, Thomas RB, Bahloul D.
    JAMA Dermatol; 2024 Aug 01; 160(8):813-821. PubMed ID: 38865146
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis.
    Puelles J, Fofana F, Rodriguez D, Silverberg JI, Wollenberg A, Dias Barbosa C, Vernon M, Chavda R, Gabriel S, Piketty C.
    Br J Dermatol; 2022 Feb 01; 186(2):285-294. PubMed ID: 34608623
    [Abstract] [Full Text] [Related]

  • 13. Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis.
    Kwatra SG, Rodriguez D, Dias-Barbosa C, Budhiarso I, Fofana F, Vernon M, Gabriel S, Piketty C, Puelles J.
    Dermatol Ther (Heidelb); 2023 Oct 01; 13(10):2403-2416. PubMed ID: 37615836
    [Abstract] [Full Text] [Related]

  • 14. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS® ) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis.
    Br J Dermatol; 2020 Nov 01; 183(5):e149-e170. PubMed ID: 33135789
    [Abstract] [Full Text] [Related]

  • 15. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
    Simpson EL, Blauvelt A, Silverberg JI, Cork MJ, Katoh N, Mark T, Schneider SKR, Wollenberg A.
    Am J Clin Dermatol; 2024 Jan 01; 25(1):139-148. PubMed ID: 37804473
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD.
    Paller AS, Gonzalez ME, Barnum S, Jaeger J, Shao L, Ozturk ZE, Korotzer A.
    Arch Dermatol Res; 2024 Jul 30; 316(8):497. PubMed ID: 39080094
    [Abstract] [Full Text] [Related]

  • 18. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
    Yosipovitch G, Gooderham MJ, Ständer S, Fonacier L, Szepietowski JC, Deleuran M, Girolomoni G, Su JC, Bushmakin AG, Cappelleri JC, Feeney C, Chan G, Thorpe AJ, Valdez H, Biswas P, Rojo R, DiBonaventura M, Myers DE.
    Am J Clin Dermatol; 2024 Jan 30; 25(1):127-138. PubMed ID: 37624488
    [Abstract] [Full Text] [Related]

  • 19. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
    Ständer S, Kwatra SG, Silverberg JI, Simpson EL, Thyssen JP, Yosipovitch G, Zhang F, Cameron MC, Cella RR, Valdez H, DiBonaventura M, Feeney C.
    Am J Clin Dermatol; 2023 Jan 30; 24(1):97-107. PubMed ID: 36512175
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.